| Frontiers in Genetics | 卷:12 |
| Network Pharmacology and Inflammatory Microenvironment Strategy Approach to Finding the Potential Target of Siraitia grosvenorii (Luo Han Guo) for Glioblastoma | |
| Kun Lv1  Lan Jiang1  Xin Zhang2  Juan Li2  De Bi3  Yunpeng Cao4  | |
| [1] Central Laboratory, Yijishan Hospital of Wannan Medical College, Wuhu, China; | |
| [2] Key Laboratory of Non-coding RNA Transformation Research of Anhui Higher Education Institution, Yijishan Hospital of Wannan Medical College, Wuhu, China; | |
| [3] Suzhou Polytechnic Institute of Agriculture, Suzhou, China; | |
| [4] Wuhan Botanical Garden, Chinese Academy of Sciences, Wuhan, China; | |
| 关键词: Siraitia grosvenorii; CCL5; glioblastoma; in silico; network pharmacology; | |
| DOI : 10.3389/fgene.2021.799799 | |
| 来源: DOAJ | |
【 摘 要 】
Background: Glioblastoma (GBM) is the most common and aggressive primary intracranial tumor of the central nervous system, and the prognosis of GBM remains a challenge using the standard methods of treatment—TMZ, radiation, and surgical resection. Traditional Chinese medicine (TCM) is a helpful complementary and alternative medicine. However, there are relatively few studies on TCM for GBM.Purpose: We aimed to find the connection between TCM and anti-GBM.Study design: Network pharmacology and inflammatory microenvironment strategy were used to predict Siraitia grosvenorii (Luo Han Guo) target for treating glioblastoma.Methods: We mainly used network pharmacology and bioinformatics.Results: CCL5 was significantly highly expressed in GBM with poor prognostics. Uni-cox and randomForest were used to determine that CCL5 was especially a biomarker in GBM. CCL5 was also the target for SG and TMZ. The active ingredient of Luo Han Guo — squalene and CCL5 —showed high binding efficiency. CCL5, a chemotactic ligand, was enriched and positively correlated in eosinophils. CCL5 was also the target of Luo Han Guo, and its effective active integrate compound –— squalene — might act on CCL5.Conclusion: SG might be a new complementary therapy of the same medicine and food, working on the target CCL5 and playing an anti-GBM effect. CCL5 might affect the immune microenvironment of GBM.
【 授权许可】
Unknown